Clinical Report: Lenvatinib Triggers Ferroptosis in Osteosarcoma Cells
Overview
This study demonstrates that lenvatinib induces ferroptosis-related changes in osteosarcoma cells, particularly through the modulation of the p-STAT3/p53/xCT pathway. The findings suggest a potential mechanism for lenvatinib's antitumor effects in osteosarcoma treatment.
Background
Osteosarcoma is a highly aggressive bone tumor primarily affecting adolescents, with significant challenges in treatment due to chemoresistance and metastasis. Current therapies, including multiagent chemotherapy and targeted treatments, have limitations that necessitate the exploration of new therapeutic strategies. Understanding the mechanisms of agents like lenvatinib could enhance treatment efficacy and improve patient outcomes.
Data Highlights
Cell Line
IC50 Values
Effects of Lenvatinib
143B
Lower
Inhibited proliferation
U2OS
Lower
Inhibited proliferation
MG63
Higher
Weaker inhibition
hFOB1.19
N/A
Limited effect
Key Findings
Lenvatinib inhibited proliferation of osteosarcoma cells in a concentration-dependent manner.
Transmission electron microscopy revealed mitochondrial alterations consistent with ferroptosis.
p53 expression was increased while xCT expression was reduced following lenvatinib treatment.
Ferrostatin-1 reversed the effects of lenvatinib on p-STAT3 and p53.
Clinical Implications
The findings indicate that lenvatinib may be a viable treatment option for osteosarcoma by inducing ferroptosis, which could enhance therapeutic outcomes. Clinicians should consider the potential of targeting ferroptosis pathways in future treatment strategies for osteosarcoma.
Conclusion
Lenvatinib's ability to induce ferroptosis through the p-STAT3/p53/xCT pathway presents a novel mechanism of action that warrants further investigation in osteosarcoma treatment.
